The abstract is read at the publisher; the summary is JClub's.
Canagliflozin ameliorated experimental ANCA-associated vasculitis in rats, reducing kidney injury, pulmonary hemorrhage, and T-lymphocyte infiltration with broad suppression of pathogenic T-cell subsets.
- Why it matters: SGLT2 inhibitors are established for chronic kidney disease, but their impact and mechanisms in ANCA-associated vasculitis remain unclear.
- What they did: The study tested canagliflozin in a rat experimental AAV model with kidney and lymph node RNA sequencing, plus mouse mechanistic experiments using adoptive transfer and immune phenotyping; it also assessed in vitro differentiation of primary human AAV T cells.
- The result: Canagliflozin-treated donor mice showed reduced splenic Th1, Th17, and CD8+ T cells and lower IFN-γ and IL-17A secretion, and their splenocytes conferred nephroprotection; in vitro, it inhibited Th1/Th17 differentiation and p38 signaling, partially reversing cytokine suppression when p38 was activated.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.